Role of MicroRNA-363 During Tumor Progression and Invasion

Overview

Journal J Physiol Biochem

Specialties Biochemistry
Physiology

Date 2024 May 1

PMID 38691273

Authors

Arya Nasimi Shad

Iman Akhlaghipour

Hawraa Ibrahim Alshakarchi

Ehsan Saburi

Meysam Moghbeli

Affiliations

Soon will be listed here.

Abstract

Recent progresses in diagnostic and therapeutic methods have significantly improved prognosis in cancer patients. However, cancer is still considered as one of the main causes of human deaths in the world. Late diagnosis in advanced tumor stages can reduce the effectiveness of treatment methods and increase mortality rate of cancer patients. Therefore, investigating the molecular mechanisms of tumor progression can help to introduce the early diagnostic markers in these patients. MicroRNA (miRNAs) has an important role in regulation of pathophysiological cellular processes. Due to their high stability in body fluids, they are always used as the non-invasive markers in cancer patients. Since, miR-363 deregulation has been reported in a wide range of cancers, we discussed the role of miR-363 during tumor progression and metastasis. It has been reported that miR-363 has mainly a tumor suppressor function through the regulation of transcription factors, apoptosis, cell cycle, and structural proteins. MiR-363 also affected the tumor progression via regulation of various signaling pathways such as WNT, MAPK, TGF-β, NOTCH, and PI3K/AKT. Therefore, miR-363 can be introduced as a probable therapeutic target as well as a non-invasive diagnostic marker in cancer patients.

References

Adan-Gokbulut A, Kartal-Yandim M, Iskender G, Baran Y . Novel agents targeting bioactive sphingolipids for the treatment of cancer. Curr Med Chem. 2012; 20(1):108-22. View

Akhlaghipour I, Fanoodi A, Zangouei A, Taghehchian N, Khalili-Tanha G, Moghbeli M . MicroRNAs as the Critical Regulators of Forkhead Box Protein Family in Pancreatic, Thyroid, and Liver Cancers. Biochem Genet. 2023; 61(5):1645-1674. DOI: 10.1007/s10528-023-10346-4. View

Akhlaghipour I, Taghehchian N, Zangouei A, Maharati A, Mahmoudian R, Saburi E . MicroRNA-377: A therapeutic and diagnostic tumor marker. Int J Biol Macromol. 2022; 226:1226-1235. DOI: 10.1016/j.ijbiomac.2022.11.236. View

An J, Wang X, Guo P, Zhong Y, Zhang X, Yu Z . Hexabromocyclododecane and polychlorinated biphenyls increase resistance of hepatocellular carcinoma cells to cisplatin through the phosphatidylinositol 3-kinase/protein kinase B pathway. Toxicol Lett. 2014; 229(1):265-72. DOI: 10.1016/j.toxlet.2014.06.025. View

Aylon Y, Ofir-Rosenfeld Y, Yabuta N, Lapi E, Nojima H, Lu X . The Lats2 tumor suppressor augments p53-mediated apoptosis by promoting the nuclear proapoptotic function of ASPP1. Genes Dev. 2010; 24(21):2420-9. PMC: 2964752. DOI: 10.1101/gad.1954410. View

Baker S, Reddy E . CDK4: A Key Player in the Cell Cycle, Development, and Cancer. Genes Cancer. 2013; 3(11-12):658-69. PMC: 3636745. DOI: 10.1177/1947601913478972. View

Balon K, Sheriff A, Jackow J, Laczmanski L . Targeting Cancer with CRISPR/Cas9-Based Therapy. Int J Mol Sci. 2022; 23(1). PMC: 8745084. DOI: 10.3390/ijms23010573. View

Bellissimo D, Speck N . Mutations in Inherited and Sporadic Leukemia. Front Cell Dev Biol. 2018; 5:111. PMC: 5742424. DOI: 10.3389/fcell.2017.00111. View

Bhagat M, Palanichamy J, Ramalingam P, Mudassir M, Irshad K, Chosdol K . HIF-2α mediates a marked increase in migration and stemness characteristics in a subset of glioma cells under hypoxia by activating an Oct-4/Sox-2-Mena (INV) axis. Int J Biochem Cell Biol. 2016; 74:60-71. DOI: 10.1016/j.biocel.2016.02.017. View

10.

Bi Y, Mao Y, Su Z, Du J, Ye L, Xu F . Long noncoding RNA HNF1A-AS1 regulates proliferation and apoptosis of glioma through activation of the JNK signaling pathway via miR-363-3p/MAP2K4. J Cell Physiol. 2020; 236(2):1068-1082. DOI: 10.1002/jcp.29916. View

11.

Boufraqech M, Zhang L, Nilubol N, Sadowski S, Kotian S, Quezado M . Lysyl Oxidase (LOX) Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in Human Cancers. Clin Cancer Res. 2016; 22(17):4491-504. PMC: 8201910. DOI: 10.1158/1078-0432.CCR-15-2461. View

12.

Cao L, Wan Q, Li F, Tang C . MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition. BMB Rep. 2018; 51(9):456-461. PMC: 6177509. View

13.

Cao W, Chen H, Yu Y, Li N, Chen W . Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021; 134(7):783-791. PMC: 8104205. DOI: 10.1097/CM9.0000000000001474. View

14.

Carter C, Allen C, Henson D . Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989; 63(1):181-7. DOI: 10.1002/1097-0142(19890101)63:1<181::aid-cncr2820630129>3.0.co;2-h. View

15.

Cham K, Soga T, Parhar I . RING Finger Protein 38 Is a Neuronal Protein in the Brain of Nile Tilapia, . Front Neuroanat. 2017; 11:72. PMC: 5583157. DOI: 10.3389/fnana.2017.00072. View

16.

Chang M, Huang C, Chen M, Chen S, Fan C, Chu J . Cloning and characterization of hMAP126, a new member of mitotic spindle-associated proteins. Biochem Biophys Res Commun. 2001; 287(1):116-21. DOI: 10.1006/bbrc.2001.5554. View

17.

Chen L, Bourguignon L . Hyaluronan-CD44 interaction promotes c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells. Mol Cancer. 2014; 13:52. PMC: 3975292. DOI: 10.1186/1476-4598-13-52. View

18.

Chen G, Sun W, Hua X, Zeng W, Yang L . Long non-coding RNA FOXD2-AS1 aggravates nasopharyngeal carcinoma carcinogenesis by modulating miR-363-5p/S100A1 pathway. Gene. 2017; 645:76-84. DOI: 10.1016/j.gene.2017.12.026. View

19.

Chen J, Wang Z, Shen X, Cui X, Guo Y . Identification of novel biomarkers and small molecule drugs in human colorectal cancer by microarray and bioinformatics analysis. Mol Genet Genomic Med. 2019; 7(7):e00713. PMC: 6625111. DOI: 10.1002/mgg3.713. View

20.

Chen Y, Chen S, Lu J, Yuan D, He L, Qin P . MicroRNA-363-3p promote the development of acute myeloid leukemia with RUNX1 mutation by targeting SPRYD4 and FNDC3B. Medicine (Baltimore). 2021; 100(18):e25807. PMC: 8104143. DOI: 10.1097/MD.0000000000025807. View